Editing Dengue fever (section)

=== Vaccine ===
{{main|Dengue vaccine}}As of March 2024, there are two vaccines to protect against dengue infection; Dengvaxia and Qdenga.<ref name="www.ecdc.europa.eu-2023">{{Cite web |date=2023-08-07 |title=Factsheet about dengue |url=https://www.ecdc.europa.eu/en/dengue-fever/facts |access-date=2024-03-08 |website=www.ecdc.europa.eu |language=en |archive-date=25 February 2024 |archive-url=https://web.archive.org/web/20240225174109/https://www.ecdc.europa.eu/en/dengue-fever/facts |url-status=live }}</ref>
[[File:Intradermal injection.jpg|alt=Subcutaneous injection|thumb|Illustration of a subcutaneous injection]]
'''Dengvaxia'''  (formerly CYD-TDV) became available in 2015, and is approved for use in the US, EU and in some Asian and Latin American countries.<ref>{{Cite web |title=Information on Dengvaxia® |url=https://www.sanofi.com/en/our-company/social-impact/responsible-business-values/information-on-dengvaxia |access-date=2024-03-08 |website=www.sanofi.com |language=en |archive-date=8 March 2024 |archive-url=https://web.archive.org/web/20240308212800/https://www.sanofi.com/en/our-company/social-impact/responsible-business-values/information-on-dengvaxia |url-status=live }}</ref> It is an attenuated virus, is suitable for individuals aged 6–45 years and protects against all four serotypes of dengue.<ref>{{Cite web |title=Dengvaxia : EPAR - Medicine overview |url=https://www.ema.europa.eu/en/documents/product-information/dengvaxia-epar-product-information_en.pdf |access-date=2024-03-09 |website=European Medicines Agency |archive-date=9 March 2024 |archive-url=https://web.archive.org/web/20240309191332/https://www.ema.europa.eu/en/documents/product-information/dengvaxia-epar-product-information_en.pdf |url-status=live }}</ref> Due to safety concerns about [[antibody-dependent enhancement]] (ADE), it should only be given to individuals who have previously been infected with dengue, in order to protect them from reinfection.<ref>{{Cite web |date=2017-12-01 |title=Sanofi restricts dengue vaccine but downplays antibody enhancement {{!}} CIDRAP |url=https://www.cidrap.umn.edu/dengue/sanofi-restricts-dengue-vaccine-downplays-antibody-enhancement |access-date=2024-03-09 |website=Center for Infectious Disease Research & Policy |language=en |archive-date=9 March 2024 |archive-url=https://web.archive.org/web/20240309191331/https://www.cidrap.umn.edu/dengue/sanofi-restricts-dengue-vaccine-downplays-antibody-enhancement |url-status=live }}</ref> It is given subcutaneously as three doses at six month intervals.<ref>{{Cite web |date=2023-04-26 |title=Administering the Dengue Vaccine |url=https://www.cdc.gov/vaccines/vpd/dengue/hcp/administration.html |access-date=2024-03-08 |website=www.cdc.gov |language=en-us |archive-date=8 March 2024 |archive-url=https://web.archive.org/web/20240308212735/https://www.cdc.gov/vaccines/vpd/dengue/hcp/administration.html |url-status=live }}</ref>

'''Qdenga''' (formerly TAK-003) completed clinical trials in 2022 and was approved for use in the European Union in December 2022;<ref name="www.ecdc.europa.eu-2023" /> it has been approved by a number of other countries including Indonesia and Brazil, and has been recommended by the [[Strategic Advisory Group of Experts|SAGE committee]] of the World Health Organization.<ref>{{Cite web |title=Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - September 2023 |url=https://www.who.int/news/item/05-10-2023-message-by-the-director-of-the-department-of-immunization--vaccines-and-biologicals-at-who---september-2023 |access-date=2024-03-08 |website=[[World Health Organization]] |language=en |archive-date=16 March 2024 |archive-url=https://web.archive.org/web/20240316010658/https://www.who.int/news/item/05-10-2023-message-by-the-director-of-the-department-of-immunization--vaccines-and-biologicals-at-who---september-2023 |url-status=live }}</ref> It is indicated for the prevention of dengue disease in individuals four years of age and older, and can be administered to people who have not been previously infected with dengue. It is a live [[Attenuated vaccine|attenuated]] vaccine containing the four serotypes of dengue virus, administered subcutaneously as two doses three months apart.<ref name="www.ecdc.europa.eu-2023" />